FI4054582T3 - Akalabrutinibin ja kapivasertibin terapeuttisia yhdistelmiä b-solumaligniteettien hoitoon - Google Patents

Akalabrutinibin ja kapivasertibin terapeuttisia yhdistelmiä b-solumaligniteettien hoitoon

Info

Publication number
FI4054582T3
FI4054582T3 FIEP20800617.1T FI20800617T FI4054582T3 FI 4054582 T3 FI4054582 T3 FI 4054582T3 FI 20800617 T FI20800617 T FI 20800617T FI 4054582 T3 FI4054582 T3 FI 4054582T3
Authority
FI
Finland
Prior art keywords
pharmaceutically acceptable
compound
formula
acceptable salt
combination
Prior art date
Application number
FIEP20800617.1T
Other languages
English (en)
Finnish (fi)
Inventor
Hannah Dry
Brandon Willis
Andrew Bloecher
Jerome Mettetal
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Application granted granted Critical
Publication of FI4054582T3 publication Critical patent/FI4054582T3/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
FIEP20800617.1T 2019-11-04 2020-10-30 Akalabrutinibin ja kapivasertibin terapeuttisia yhdistelmiä b-solumaligniteettien hoitoon FI4054582T3 (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962930208P 2019-11-04 2019-11-04
PCT/EP2020/080493 WO2021089419A1 (en) 2019-11-04 2020-10-30 Therapeutic combinations of acalabrutinib and capivasertib to treat b-cell malignancies

Publications (1)

Publication Number Publication Date
FI4054582T3 true FI4054582T3 (fi) 2025-12-04

Family

ID=73043259

Family Applications (1)

Application Number Title Priority Date Filing Date
FIEP20800617.1T FI4054582T3 (fi) 2019-11-04 2020-10-30 Akalabrutinibin ja kapivasertibin terapeuttisia yhdistelmiä b-solumaligniteettien hoitoon

Country Status (14)

Country Link
US (1) US12691113B2 (cg-RX-API-DMAC7.html)
EP (1) EP4054582B1 (cg-RX-API-DMAC7.html)
JP (1) JP7575454B2 (cg-RX-API-DMAC7.html)
KR (1) KR102984130B1 (cg-RX-API-DMAC7.html)
CN (1) CN114728003B (cg-RX-API-DMAC7.html)
AU (1) AU2020381240C1 (cg-RX-API-DMAC7.html)
CA (1) CA3158321A1 (cg-RX-API-DMAC7.html)
DK (1) DK4054582T3 (cg-RX-API-DMAC7.html)
ES (1) ES3055126T3 (cg-RX-API-DMAC7.html)
FI (1) FI4054582T3 (cg-RX-API-DMAC7.html)
MX (1) MX2022005250A (cg-RX-API-DMAC7.html)
PL (1) PL4054582T3 (cg-RX-API-DMAC7.html)
PT (1) PT4054582T (cg-RX-API-DMAC7.html)
WO (1) WO2021089419A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023230286A2 (en) * 2022-05-25 2023-11-30 Onconova Therapeutics, Inc. Methods and compositions for treating cancer
WO2024104561A1 (en) * 2022-11-15 2024-05-23 Astrazeneca Ab Therapeutic combinations of capivasertib and venetoclax

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0818533B8 (pt) 2007-10-11 2021-05-25 Astrazeneca Ab composto, composição farmacêutica, uso de um composto, e, processo para a preparação de um composto
CN103889987B (zh) 2011-07-19 2016-09-14 默沙东有限责任公司 作为btk抑制剂的选择的咪唑并吡嗪类
AU2014360537B2 (en) * 2013-12-04 2017-09-07 Gilead Sciences, Inc. Methods for treating cancers
EP3076974A1 (en) * 2013-12-05 2016-10-12 Acerta Pharma B.V. Therapeutic combination of a pi3k inhibitor and a btk inhibitor
JP6785804B2 (ja) * 2015-06-23 2020-11-18 ギリアド サイエンシズ, インコーポレイテッド B細胞悪性腫瘍を治療するための組合せ療法
US20170071962A1 (en) 2015-09-11 2017-03-16 Acerta Pharma B.V. Therapeutic Combinations of a Proteasome Inhibitor and a BTK Inhibitor
BR112017002594A2 (pt) * 2015-12-17 2017-12-19 Gilead Sciences Inc compostos inibidores de cinase de ligação de tank
CN107344940B (zh) * 2016-05-06 2020-04-21 广东东阳光药业有限公司 Btk抑制剂及其用途
WO2018097977A1 (en) * 2016-11-22 2018-05-31 Gilead Sciences, Inc. Crystalline forms of a phosphate complex of a bet inhibitor
AU2018335617B2 (en) * 2017-09-25 2021-12-09 Astrazeneca Ab Combination of a BTK inhibitor and an inhibitor of CDK9 to treat cancer
TW202014184A (zh) * 2018-04-30 2020-04-16 瑞典商阿斯特捷利康公司 用於治療癌症之組合
KR20250119664A (ko) 2018-08-29 2025-08-07 아세르타 파마. 비.브이. 4-{8-아미노-3-[(2S)-1-(부트-2-이노일)-피롤리딘-2-일]이미다조[1,5-a]-피라진-1-일}N-(피리딘-2-일)-벤즈아미드의제조 공정

Also Published As

Publication number Publication date
JP7575454B2 (ja) 2024-10-29
JP2023501317A (ja) 2023-01-18
PL4054582T3 (pl) 2026-02-16
EP4054582B1 (en) 2025-09-03
CA3158321A1 (en) 2021-05-14
KR20220098175A (ko) 2022-07-11
EP4054582A1 (en) 2022-09-14
DK4054582T3 (da) 2025-12-01
PT4054582T (pt) 2025-12-10
AU2020381240C1 (en) 2024-02-15
WO2021089419A1 (en) 2021-05-14
AU2020381240A1 (en) 2022-06-23
US20220401442A1 (en) 2022-12-22
KR102984130B1 (ko) 2026-07-01
CN114728003A (zh) 2022-07-08
US12691113B2 (en) 2026-07-28
AU2020381240B2 (en) 2023-09-07
MX2022005250A (es) 2022-06-08
ES3055126T3 (en) 2026-02-10
CN114728003B (zh) 2025-01-28

Similar Documents

Publication Publication Date Title
FI3788047T3 (fi) Fgft-estäjän kiinteitä muotoja ja menetelmiä niiden valmistamiseksi
FI3782612T3 (fi) Sytidiinianalogien oraalisia formulaatioita ja menetelmiä niiden käyttämiseksi
RU2011102797A (ru) Противоопухолевые комбинации из 4-анилино-3-цианохинолинов и капецитабина
DE60032749D1 (de) Stabilisierte pharmazeutische zusammensetzung enthaltend einen nichtsteroiden entzündungshemmenden wirkstoff und prostaglandin
RU2010151952A (ru) Водорастворимые аналоги ацетаминофена
RU2014111069A (ru) Лекарственные формы ингибитора гистондиацетилазы в комбинации с бендамутином и их применение
JP2011529968A5 (cg-RX-API-DMAC7.html)
PT1173178E (pt) Composicao compreendendo apomorfina e sildenafil e utilizacao da mesma para o tratamento da disfuncao erectil
BRPI0816317A2 (pt) Método para tratar o estresse oxidativo e melhorar a memória de trabalho pela administração de pterostilbeno
WO2005058233A3 (en) Methods for treatment of acute pancreatitis
WO2007012019A3 (en) Medicaments containing famotidine and ibuprofen and administration of same
WO2017106714A1 (en) Methods and compositions for treating peripheral neuropathy
MX2024010637A (es) Nuevas combinaciones terapeuticas para el tratamiento de enfermedades pulmonares intersticiales fibrosantes progresivas.
FI4255563T3 (fi) 5’-o-fenyyliasetyyliuridiini ja terapeuttinen käyttö
MX2024006270A (es) Nueva composicion farmaceutica oral y regimen de dosificacion para la terapia de enfermedades pulmonares intersticiales fibrosantes progresivas.
ES2503540T3 (es) Composición farmacéutica que combina un agente antiinflamatorio no esteroideo y un agente anticonvulsionante
DE60026491D1 (de) Melagatran zur behandlung von entzündungen
MX2026001173A (es) Moduladores del potencial de receptor transitorio melastatina 3 (trpm3) para el tratamiento del dolor
RU2006139819A (ru) Применение симетикона для предрасположенных к запорам пациентов
JP2022512158A5 (cg-RX-API-DMAC7.html)
JP2023501317A5 (cg-RX-API-DMAC7.html)
TW200633700A (en) Methods of using temozolomide formulation intrathecally in the treatment of cancers
JP2008503445A5 (cg-RX-API-DMAC7.html)
RU2010154623A (ru) Производные 1-аминоалкилциклогексана для лечения расстройств сна
HUP0400495A2 (hu) Apomorfin szájnyálkahártyán keresztül történő adagolására szolgáló orális készítmény